EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Pirfenidone Alleviates Inflammation and Fibrosis of Acute Respiratory Distress Syndrome by Modulating the Transforming Growth Factor-β/Smad Signaling Pathway

Seung Sook Paik, Jeong Mi Lee, Il-Gyu Ko, Sae Rom Kim iD, Sung Wook Kang, Jin An iD, Jin Ah Kim, Dongyon Kim, Lakkyong Hwang, Jun-Jang Jin, Sang-Hoon Kim iD, Jun-Youl Cha und 1 weitere

International Journal of Molecular Sciences · 23.07.2024 · 25 (15) · 8014

DOI: 10.3390/ijms25158014 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 23.07.2024. Verfasst von Seung Sook Paik und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Graduate School, Kyung Hee University, Seoul 02447, Republic of Korea. Hauptthemen laut MEDLINE: Pyridones, Respiratory Distress Syndrome, Signal Transduction, Bleomycin. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Korea.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Acute respiratory distress syndrome (ARDS) occurs as an acute onset condition, and patients present with diffuse alveolar damage, refractory hypoxemia, and non-cardiac pulmonary edema. ARDS progresses through an initial exudative phase, an inflammatory phase, and a final fibrotic phase. Pirfenidone, a powerful anti-fibrotic agent, is known as an agent that inhibits the progression of fibrosis in idiopathic pulmonary fibrosis. In this study, we studied the treatment efficiency of pirfenidone on lipopolysaccharide (LPS) and bleomycin-induced ARDS using rats. The ARDS rat model was created by the intratracheal administration of 3 mg/kg LPS of and 3 mg/kg of bleomycin dissolved in 0.2 mL of normal saline. The pirfenidone treatment group was administered 100 or 200 mg/kg of pirfenidone dissolved in 0.5 mL distilled water orally 10 times every 2 days for 20 days. The administration of LPS and bleomycin intratracheally increased lung injury scores and significantly produced pro-inflammatory cytokines. ARDS induction increased the expressions of transforming growth factor (TGF)-β1/Smad-2 signaling factors. Additionally, matrix metalloproteinase (MMP)-9/tissue inhibitor of metalloproteinase (TIMP)-1 imbalance occurred, resulting in enhanced fibrosis-related factors. Treatment with pirfenidone strongly suppressed the expressions of TGF-β1/Smad-2 signaling factors and improved the imbalance of MMP-9/TIMP-1 compared to the untreated group. These effects led to a decrease in fibrosis factors and pro-inflammatory cytokines, promoting the recovery of damaged lung tissue. These results of this study showed that pirfenidone administration suppressed inflammation and fibrosis in the ARDS animal model. Therefore, pirfenidone can be considered a new early treatment for ARDS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PyridonesRespiratory Distress SyndromeSignal TransductionBleomycinLipopolysaccharidesAnimalsRatsMaleTissue Inhibitor of Metalloproteinase-1Smad2 ProteinRats, Sprague-DawleyInflammationDisease Models, AnimalMatrix Metalloproteinase 9Transforming Growth Factor beta1Transforming Growth Factor betaLungSmad Proteins

Stichwörter der Autor:innen

acute respiratory distress syndromebleomycininflammationlipopolysaccharidepirfenidonepulmonary fibrosis

Substanzen

pirfenidonePyridonesBleomycinLipopolysaccharidesTissue Inhibitor of Metalloproteinase-1Smad2 ProteinMatrix Metalloproteinase 9Transforming Growth Factor beta1Smad2 protein, ratTransforming Growth Factor beta

Autor:innen und Institutionen

  • Department of Medicine, Graduate School, Kyung Hee University, Seoul 02447, Republic of Korea.
  • Department of Pulmonary, Allergy and Critical Care Medicine, Kyung Hee University Hospital at Gangdong, College of Medicine, Kyung Hee University, Seoul 05278, Republic of Korea.
  • Research Support Center, School of Medicine, Keimyung University, Deagu 42601, Republic of Korea.
  • Department of Nursing, Graduate School, Kyung Hee University, Seoul 02447, Republic of Korea.
  • Team of Efficacy Evaluation, Orient Genia Inc., Seongnam 13201, Republic of Korea.
  • Department of Neurosurgery, Rutgers Robert Wood Johnson Medical School, The Stat University of New Jersey, Piscataway, NJ 08854, USA.

ORCID-Profile: Sae Rom Kim, Jin An, Sang-Hoon Kim

Förderung

  • National Research Foundation of Korea

Zitieren

APA

Paik, S. S., Lee, J. M., Ko, I. G., Kim, S. R., Kang, S. W., An, J., Kim, J. A., Kim, D., Hwang, L., Jin, J. J., Kim, S. H., Cha, J. Y., & Choi, C. W. (2024). Pirfenidone Alleviates Inflammation and Fibrosis of Acute Respiratory Distress Syndrome by Modulating the Transforming Growth Factor-β/Smad Signaling Pathway. International Journal of Molecular Sciences, 25(15), 8014. https://doi.org/10.3390/ijms25158014

Vancouver

Paik SS, Lee JM, Ko IG, Kim SR, Kang SW, An J, et al. Pirfenidone Alleviates Inflammation and Fibrosis of Acute Respiratory Distress Syndrome by Modulating the Transforming Growth Factor-β/Smad Signaling Pathway. International Journal of Molecular Sciences. 2024;25(15):8014. doi:10.3390/ijms25158014

BibTeX
@article{Paik2024,
  author = {Paik, Seung Sook and Lee, Jeong Mi and Ko, Il-Gyu and Kim, Sae Rom and Kang, Sung Wook and An, Jin and Kim, Jin Ah and Kim, Dongyon and Hwang, Lakkyong and Jin, Jun-Jang and Kim, Sang-Hoon and Cha, Jun-Youl and Choi, Cheon Woong},
  title = {Pirfenidone Alleviates Inflammation and Fibrosis of Acute Respiratory Distress Syndrome by Modulating the Transforming Growth Factor-β/Smad Signaling Pathway},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  volume = {25},
  number = {15},
  pages = {8014},
  doi = {10.3390/ijms25158014}
}
Kostenlos starten →